Menu
1. LEUCEMIES MYELOIDES AIGUES DU SUJET AGE
2. AML DEFINITION
3. EPIDEMIOLOGY
4. AML INCIDENCE
5. SURVIVAL RATES
6. SURVIVAL BY AGE
7. OLDER PATIENTS ARE ARDER TO TREAT
8. RISK STRATIFICATION
9. AML PATIENT FITNESS ASSESSMENT
10. AML PATIENT FITNESS ASSESSMENT (2)
11. COMORBIDITIES ASSESSMENT
12. COMORBIDITIES ASSESSMENT
13. AML RISK STRATIFICATION
14. ELN 2017 CLASSIFICATION
15. INTENSIVE INDUCTION THERAPY
16. INTENSIVE INDUCTION TREATMENT
17. INTENSIVE CONSOLIDATION
18. ALLO-SCT IS FEASABLE IN ELDERLY AML PATIENTS
19. OUTCOMES OF HAPLO-IDENTICAL ALLO-SCT IN ELDERLY AML PATIENTS
20. NON INTENSIVE TREATMENT
21. HYPO-METHYLATING AGENTS
22. HYPO-METHYLATING AGENTS
23. HYPO-METHYLATING AGENTS
24. COMPARISON INTENSIVE VS PALLIATIVE TREATMENT IN ELDERLY AML PATIENTS
25. CAN WE IMPROVE ELDERLY AML PATIENTS TREATMENT
26. GEMTUZUMAB OZOGAMICINE MYLOTARG
27. VYXEOS
28. VENETOCLAX
29. CONCLUSION
30. FUTURE DIRECTIONS
31. MERCI POUR VOTRE ATTENTION
Leucémies myéloïdes aigues du sujet âgé, Dre S. Morin, 02.04.19
Resources
Here are some useful links and documents:
Title
Title
Title
FINISH
SUBMIT
NEXT
PREV
Submit All
